We did not observe any statistically significant correlations between CDX2 loss/reduction or BRAFT1799A mutation and patient age, tumor location, or selected tumor histological features, other than the absence of ‘dirty necrosis’ was associated with BRAF mutations (p=0.03) (Figure 1—source data 1). The gene discussed is BRAF; the disease is neoplasm.